Business
TG Therapeutics Announces Data for Ublituximab in Multiple Sclerosis Presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
New ULTIMATE I & II data presented at ECTRIMS shows ublituximab treatment is associated with significant improvement in the multiple sclerosis functional
About this update from Tg Therapeutics, Inc.
[{"type":"text","content":"New ULTIMATE I & II data presented at ECTRIMS shows ublituximab treatment is associated with significant improvement in the multiple sclerosis functional composite (MSFC) score Data from the ULTIMATE I & II Phase 3 trials recently supported a BLA submission to the U.S. FDA for ublituximab to treat patients with RMS Webcast with key opinion leaders/investigators to be held today, Thursday, October 14, 2021 at 12:30 PM ET NEW YORK, Oct. 14, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations, including additional analyses from two global, active-controlled, Phase 3 studies, called ULTIMATE I & II, evaluating ublituximab, the Company’s investigational novel, glycoengineered anti-CD20 monoclonal antibody, compared to teriflunomide, in patients with relapsing forms of multiple sclerosis (RMS). As previously reported, both studies met their primary endpoint with ublituximab treatment demonstrating a statistically significant reduction in annualized relapse rate (ARR) over a 96-week period (p","length":1339,"tagName":"div"}]